Recombinant Human Serum Amyloid A1 Protein Summary
Recombinant bioactive protein containing 18 amino acids for Human Serum Amyloid A1
Source:E. coli
Amino Acid Sequence:(P0DJI8)
Method
>98% SDS-PAGE
For most in vitro applications, apo-SAA exerts its biological activity in the concentration range of 10-50 ug/ml.
E. coli
Biologically Active Protein
SAA1
>95%, by SDS-PAGE
<0.1 ng/ug
Applications/Dilutions
11.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Packaging, Storage & Formulations
Store at -20 to -80C. Avoid freeze-thaw cycles.
Lyophilized with no additives
Lyoph
>95%, by SDS-PAGE
Reconstitute in 0.1% acetic acid to a concentration of 1 g/l. This solution can then be diluted into other aqueous buffers.
Alternate Names for Recombinant Human Serum Amyloid A1 Protein
- MGC111216
- PIG4
- SAA
- SAA1
- SAA2
- serum amyloid A protein
- Serum Amyloid A1
- TP53I4
- tumor protein p53 inducible protein 4
Background
Human apo-SAA is a 104 amino acid polypeptide that circulates primarily in association with high-density lipoproteins (HDL). The level of apo-SAA, normally 1-5ug/ml in plasma, increases 500-1000 fold within 24 hours of an inflammatory stimulus and, under these conditions, is the most abundant HDL apo-lipoprotein. The human SAA gene codes for a 122 amino acid polypeptide, which contains an 18 amino acid N-terminal signal sequence.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 2 years from date of receipt.